Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU1-132P (RNA, U1 small nuclear 132, pseudogene) is annotated as a pseudogene of the U1 small nuclear RNA (snRNA) family. U1 snRNAs are small non-coding RNAs fundamental for the splicing of pre-mRNA by recognizing the 5′ splice site and recruiting the spliceosome complex[1][3][5]. However, as a **pseudogene**, RNU1-132P is not believed to produce a functional RNA product or participate in splicing or any canonical pathway. Pseudogenes often arise via duplication or retrotransposition and lose their ability to code for functional RNA or proteins. There is no evidence that RNU1-132P acts as a receptor, enzyme, transporter, or any other conventional therapeutic target class. Although mutations and structural variation in canonical U1 snRNA loci have been linked to splicing alterations in cancer[4], no such association has been described for this specific pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U1 small nuclear 132, pseudogene (RNU1-132P).